160115-34-4

Upstream product

• 5396-89-4 benzyl acetoacetate 
• 74-88-4 methyl iodide 
• 75-36-5 acetyl chloride 
• 75107-16-3 2-bromoisobutyric acid,benzyl ester 
• 597-04-6 ethyl 2,2-dimethyl-3-oxobutanoate 
• 100-51-6 benzyl alcohol 

Downstream Products

• 49714-52-5 2,2,3-trimethylbutanoic acid 
• 4168-01-8 2,2,3-trimethyl-3-butenoic acid 

Relevant academic research and scientific papers

3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR

The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor

A series of 3(R)-aminopyrrolidine derivatives were designed and synthesized for JAK1-selective inhibitors through the modification of tofacitinib's core structure, (3R,4R)-3-amino-4-methylpiperidine. From the new core structures, we selected (R)-N-methyl-N-(pyrrolidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine as a scaffold for further SAR studies. From biochemical enzyme assays and liver microsomal stability tests, (R)-3-(3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile (6) was chosen for further in vivo test through oral administration. Compound 6 showed improved selectivity for JAK1 compared to that of tofacitinib (IC50 11, 2.4 × 102, 2.8 × 103, and 1.1 × 102 nM for JAK1, JAK2, JAK3, and TYK2, respectively). In CIA and AIA model tests, compound 6 exhibited similar efficacy to tofacitinib citrate.

JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF

Janus kinase 1 selective inhibitors and pharmaceutical use thereof are provided.

COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Preparation of organomanganese reagents from organic halides with activated manganese

Reduction of Li2MnCl4 with magnesium metal provided activated manganese as a black suspension in THF. Treatment of organic halides such as allyl bromides, α-halo esters or aryl halides with activated manganese furnished various organomanganese reagents which reacted further with electrophiles to afford the corresponding adducts. The reaction of a ketone bearing an iodoaryl moiety with this active manganese induced cyclization to provide dihydroindene derivative.

Synthesis of chiral succinates via Pd(0) catalyzed carbonylation/asymmetric hydrogenation sequence

We report a novel 4 step synthesis of chiral trisubstituted succinic acid derivatives utilizing carbonylation of a vinyl triflate followed by catalytic asymmetric hydrogenation to yield the title compounds.

Novel Template Effects of Distannoxane Catalysts in Highly Efficient Transesterification and Esterification

The transesterification of carboxylic esters and the esterification of carboxylic acids are effected under mild conditions under catalysis by 1,3-disubstituted tetraalkyldistannoxanes 1.Various functional groups remain unaffected and otherwise difficult to obtain esters are accessible.An ester bearing a tertiary butyl group in the carboxylic acid moiety remained unchanged in competition experiments with a less bulky ester, which undergoes transesterification quantitatively.The unique features of the reactions are attributable to the template effects of the dimeric structure of 1.The facility with which compounds 1 can be converted into alkoxystannoxanes 2 and the synergistic effect of the proximate tin atoms of 2 play key roles in permitting smooth reactions and high selectivity.Another notable feature of compounds 1 is their unusually high solubility in organic solvents, even though the compounds have a metaloxane core as a major skeletal part.The double-layered structure of 1, in which the inorganic moiety is surrounded by eight alkyl groups, permits esterification to be driven to completion simply by heating a mixture of the carboxylic acid and the alcohol.The distannoxane-catalyzed esterification is irreversible, and thus, no hydrolysis of the product esters occurs when compounds 1 are used as catalysts.

NOVEL DISTANNOXANE-CATALYZED TRANSESTERIFICATION AND A NEW ENTRY TO α,β-UNSATURATED CARBOXYLIC ACIDS

Novel distannoxane-catalyzed transesterification reaction has been developed which affords various types of esters under very mild conditions.The reaction was applied to the stereo- and regioselective synthesis of trisubstituted α,β-unsaturated carboxylic acids.